{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:01Z","timestamp":1791925321469,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of this study was to characterize the safety profile of linezolid in patients with renal impairment compared with patients without renal impairment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A population-based retrospective cohort study using linked administrative databases included patients aged 66 years or older in Ontario, Canada<\/jats:p>\n                  <jats:p>who were prescribed linezolid from 2014 to 2021. Renal impairment was defined using baseline estimated glomerular filtration rate &amp;lt;30\u2005mL\/min\/1.73\u2005m2 or receipt of dialysis. The primary outcomes were change in platelet count and severe thrombocytopenia (platelet count &amp;lt;50 \u00d7 109\/L) within 90 days. Secondary outcomes included bleeding, neutropenia, peripheral neuropathy, optic neuropathy, acidosis, serotonin syndrome, and mortality. Inverse probability of treatment weighting on propensity score was used to balance comparison groups on baseline health.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 625 patients, 98 (15.7%) patients had renal impairment. The mean (SD) platelet change was \u221288.3 (108.4) 109\/L in the renal impairment group and \u221276.5 (109.8) 109\/L in the no renal impairment group, with an adjusted mean difference of \u221229.4 (95% CI, \u221253.4 to \u22125.3; P = .0165). Severe thrombocytopenia occurred in 9.2% for the renal impairment group and 5.9% for the no renal impairment group, with an adjusted risk difference of 2.7% (95% CI, \u22123.1% to 8.6%; P = .3655). There were no significant differences in secondary outcomes between the 2 groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with renal impairment on linezolid therapy had a larger decrease in platelet count, but their risks for severe thrombocytopenia and bleeding were not significantly different than patients without renal impairment. Linezolid is likely safe in renal impairment without dose adjustment or drug level monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac669","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T09:48:35Z","timestamp":1670838515000},"source":"Crossref","is-referenced-by-count":5,"title":["Safety Profile of Linezolid in Older Adults With Renal Impairment: A Population-Based Retrospective Cohort Study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-9934","authenticated-orcid":false,"given":"Anthony D","family":"Bai","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Queen's University , Kingston, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McKenna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Kingston Health Sciences Centre , Kingston, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Kingston Health Sciences Centre , Kingston, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Loeb","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University , Hamilton, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep S","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Geriatric Medicine, Department of Medicine, Queen's University , Kingston, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"2022123008510902700_ofac669-B1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1155\/2006\/818535","article-title":"An assessment of linezolid utilization in selected Canadian provinces","volume":"17","author":"Walker","year":"2006","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2022123008510902700_ofac669-B2","article-title":"Zyvox","author":"US Food and Drug Administration"},{"key":"2022123008510902700_ofac669-B3","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2022123008510902700_ofac669-B4","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","article-title":"Pharmacokinetics of linezolid in subjects with renal dysfunction","volume":"47","author":"Brier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2022123008510902700_ofac669-B5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcp.14965","article-title":"Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"88","author":"Shi","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2022123008510902700_ofac669-B6","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2022123008510902700_ofac669-B7","doi-asserted-by":"crossref","first-page":"e12114","DOI":"10.1097\/MD.0000000000012114","article-title":"The risk factors of linezolid-induced lactic acidosis: a case report and review","volume":"97","author":"Mao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022123008510902700_ofac669-B8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2022123008510902700_ofac669-B9","article-title":"ICES data","author":"Institute for Clinical Evaluative Sciences"},{"key":"2022123008510902700_ofac669-B10","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2022123008510902700_ofac669-B11","article-title":"Sandoz linezolid","author":"Government of Ontario"},{"key":"2022123008510902700_ofac669-B12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022123008510902700_ofac669-B13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2022123008510902700_ofac669-B14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022123008510902700_ofac669-B15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1378\/chest.13-0121","article-title":"Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes","volume":"144","author":"Williamson","year":"2013","journal-title":"Chest"},{"key":"2022123008510902700_ofac669-B16","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus"},{"key":"2022123008510902700_ofac669-B17","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/jth.15368","article-title":"Definition of a critical bleed in patients with immune thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Sirotich","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2022123008510902700_ofac669-B18","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022123008510902700_ofac669-B19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"2022123008510902700_ofac669-B20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"2022123008510902700_ofac669-B21","first-page":"CD002042","article-title":"Transfusion thresholds for guiding red blood cell transfusion","volume":"12","author":"Carson","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2022123008510902700_ofac669-B22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch Intern Med"},{"key":"2022123008510902700_ofac669-B23","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/sim.3854","article-title":"The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies","volume":"29","author":"Austin","year":"2010","journal-title":"Stat Med"},{"key":"2022123008510902700_ofac669-B24","doi-asserted-by":"crossref","first-page":"d2304","DOI":"10.1136\/bmj.d2304","article-title":"How to obtain the P value from a confidence interval","volume":"343","author":"Altman","year":"2011","journal-title":"BMJ"},{"key":"2022123008510902700_ofac669-B25","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1177\/0962280218781171","article-title":"Propensity score weighting analysis and treatment effect discovery","volume":"28","author":"Mao","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2022123008510902700_ofac669-B26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"key":"2022123008510902700_ofac669-B27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/trf.12943","article-title":"Platelet transfusion: a systematic review of the clinical evidence","volume":"55","author":"Kumar","year":"2015","journal-title":"Transfusion"},{"key":"2022123008510902700_ofac669-B28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000201313.24970.b8","article-title":"Linezolid-associated toxic optic neuropathy","volume":"66","author":"Rucker","year":"2006","journal-title":"Neurology"},{"key":"2022123008510902700_ofac669-B29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2022123008510902700_ofac669-B30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2014.12.009","article-title":"Incidence and risk factors of linezolid-induced lactic acidosis","volume":"31","author":"Im","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2022123008510902700_ofac669-B31","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.26.12.1784","article-title":"Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists","volume":"26","author":"Huang","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2022123008510902700_ofac669-B32","doi-asserted-by":"crossref","first-page":"e00605\u201319","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022123008510902700_ofac669-B33","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/DDDT.S303497","article-title":"Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2022123008510902700_ofac669-B34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022123008510902700_ofac669-B35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jac\/dkr467","article-title":"Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data","volume":"67","author":"Butterfield","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2022123008510902700_ofac669-B36","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022123008510902700_ofac669-B37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2022123008510902700_ofac669-B38","doi-asserted-by":"crossref","first-page":"e0040822","DOI":"10.1128\/aac.00408-22","article-title":"Linezolid exposure is associated with cytopenias in patients treated for multidrug-resistant tuberculosis","volume":"66","author":"Graciaa","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac669\/47783426\/ofac669.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/12\/ofac669\/48446764\/ofac669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/12\/ofac669\/48446764\/ofac669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T11:42:58Z","timestamp":1672400578000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac669\/6887594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac669","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,12,1]]},"article-number":"ofac669"}}